fetalhandlingof,84
inhemostasis,1289
Calcium-channelblockers
forpulmonaryhypertension,1389
forsystemichypertension,1139,1140t
Calories
inadequateintakeof,1495
maximizing,1502
CanadianOutcomesRegistryLateAfterTetralogyofFallotRepair,1511t–1514t
Cancer,childhood,survivorsof,exercisetestingof,401
Cancertherapy-relatedcardiotoxicity(CTC)
activityrestrictionsandmodifiableriskfactorsfor,1172
advancedheartfailuretherapyfor,1172
alternatedosingschedulesandanthracyclinederivativesin,1171
ambulatoryrhythmmonitoringin,1171
cardiacmagneticresonancein,1170
cardioprotectionandpreventionfor,1171–1172
developmentof,1167,1168f
dexrazoxanefor,1171
echocardiographyin,1170
electrocardiographyin,1170
exercisetestingin,1171
implantablecardiacdefibrillatorsfor,1172
mechanismsof,1167,1169f
medicaltherapyfor,1172
multigatedradionuclideangiographyin,1171
othermedicaltherapiesandinterventionsfor,1171–1172
patientandtreatmentriskfactorsfor,1167,1169f,1169b
serumbiomarkersin,1170–1171
stressechocardiographyin,1171
surveillanceofpatientsthroughtherapyandbeyond,1170–1171
therapeuticoptionsfor,1172
Cannulation,considerationsfor,inprematurity,213
Capacity,1469t
Captopril,forhypertension,1140t
Carbamazepine,forcarditis,1017t
Cardiacabnormalities,functional,449–450
Cardiacanatomy,17–26
ofarterialtrunks,25–26,26f
ofbloodsupply,30–32
ofchambers,17–18,20f
leftatriumand,21–22,21f–22f
leftventricleand,24–25,24f–26f
rightatriumand,18–21,20f–21f
rightventricleand,22–24,22f–24f
ofconductiontissues,28–30,29f
offibrousskeleton,28,28f
locationofheartinchestand,17–26,18f–20f
normal,echocardiographic,286–300,286f–288f
anatomyprinciplesofechocardiography,288–289,288f–289f
ofvalves,26–28
Cardiacandnoncardiacsurgery,inchildwithcongenitalcardiacdisease,
anestheticconsiderationsfor,1547–1552
fordiagnosticandinterventionalcatheterization,1551
exposureonbraindevelopment,effectsof,1552
managementof,1548–1549
monitoringandvascularaccessof,1550
postoperativecare,fast-trackingandtransitionto,1550–1551
preoperativeassessmentof,1547–1548,1548t
preparationandpreproceduralsedationof,1548
Cardiacarrest,managementof,inFontanpathway,1293–1294
Cardiaccatheterization
incommonarterialtrunk,750–751,751f
forcongenitallymalformedhearts,210
inFontancirculation,1340–1342
aortopulmonarycollateralembolizationand,1342
fenestrationclosureand,1340–1342,1341f
venovenouscollateralsand,1341,1342f
inKawasakidisease,987
forpulmonaryhypertension,1388
Cardiaccenterteam,ofteams,1491,1492f
Cardiaccomputedtomography,332–333,332f
contrastagentsin,333
Cardiaccrescent,50,60f
foldingof,33,34f
Cardiacdayunit,1482t
Cardiacdevelopment,50–52
fetal,87–90
genesregulation,50
growthfactorsin,51
hemodynamicsand,51–52
micro-RNAregulationof,51
originsofheartand,50
transcriptionfactorsin,50–51
Cardiacdisease
acquiredandcongenital
pharmacogeneticsintreatmentof,duringchildhood,1429–1440
ethicalissuesand,1472
prematurityand,189–213
Cardiacelectricaldevices,historyof,364–365
Cardiacembryology,33–47
atrialseptationand,38–40,38f–39f
ofatrioventricularcanal,40,40f
cardiacloopformationand,34–35,34f
ofcardiacsegments,35–36,35f–36f
circulationand,83,84f
ofconductionsystem,46
hearttubeoriginand,33,34f
myocardialvascularizationand,46–47
ofoutletsegment,42–45,42f–45f